trending Market Intelligence /marketintelligence/en/news-insights/trending/KgphWhHMhks53Sw3GAXNgg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Jounce Therapeutics to raise $101.8M in IPO


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

Jounce Therapeutics to raise $101.8M in IPO

Jounce Therapeutics Inc. plans to raise approximately $101.8 million in its IPO of 6,365,000 shares.

The clinical-stage immunotherapy company priced its offering at $16 apiece and offered underwriters a 30-day option to purchase up to an additional 954,750 of the shares offered.

The shares are scheduled to begin trading on Nasdaq on Jan. 27 under the JNCE ticker symbol.

J.P. Morgan and Cowen and Co. are acting as joint book-running managers for the offering. Meanwhile, Wells Fargo Securities is acting as lead manager and Baird is acting as a co-manager for the offering.